Eugenia jambolana extract reduces the systemic exposure of Sitagliptin and improves conditions associated with diabetes: A pharmacokinetic and a pharmacodynamic herb-drug interaction study

10.1016/j.jtcme.2018.10.001

A. Vora；A. Varghese；Y. Kachwala；M. Bhaskar；A. Laddha；A. Jamal；P. Yadav

Eugenia jambolana ； Sitagliptin ； Pharmacodynamics ； Pharmacokinetic ； Herb-drug interaction

Journal of Traditional and Complementary Medicine

9卷4期（2019 / 10 / 01）

364 - 371

英文

Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus. This herb is globally marketed as single or multi herb formulations. Many diabetes patients consume EJ extract oral hypoglycemic drugs together. This calls for a need to assess risks versus benefit of this co-administration. In present investigation, pharmacodynamic and pharmacokinetic interactions of aqueous extract of EJ seeds at the dose of 400 mg/kg are studied with 10 mg/kg of oral hypoglycaemic drug sitagliptin (SITA) by co-administrating them for 28 days in streptozotocin (STZ) induced diabetic rats. The pharmacokinetic parameters of SITA were determined using HPLC-ESI-MS/MS and it was found that the combination treatment reduces the systemic exposure of SITA by showing 38.70% reduction in concentration maximum (Cmax) and 22.40% reduction in area under curve (AUC). Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study. In addition, the liver function, the kidney function and the lipid parameters were found to be significantly improved and beneficial effects were found with respect to food intake and water intake and urine output in case of combination treatment groups when compared with individual treatment groups. Histopathological examination of pancreatic tissue suggests its significant recovery of having normal acinus with better cell protection in combination treatment. In conclusion, the combination treatment demonstrated reduced systemic exposure of SITA without compromising on its antihyperglycemic activity and improvement in conditions associated with diabetes.

1. An, G,Mukker, JK,Derendorf, H,Frye, RF(2015).Enzyme- and transporter-mediated beverage-drug interactions: an update on fruit juices and green tea.J Clin Pharmacol,55(12),1313-1331.
2. Aqil, F,Gupta, A,Munagala, R(2012).Antioxidant and antiproliferative activities of anthocyanin/ellagitannin-enriched extracts from Syzygium cumini L. ( Jamun, the indian blackberry).Nutr Canc,64(3),428-438.
3. Berginc, K,Kristl, A(2013).The mechanisms responsible for garlic - drug interactions and their in vivo relevance.Curr Drug Metabol,14(1),90-101.
4. Chaturvedi, A,Bhawani, G,Agarwal, PK,Goel, S,Singh, A,Goel, RK.Antidiabetic and antiulcer effects of extract of Eugenia jambolana seed in mild diabetic rats: study on gastric mucosal offensive acid-pepsin secretion.Indian J Physiol Pharmacol,53(2),137-146.
5. Chen, M,Zhou, S,Fabriaga, E,Zhang, P,Zhou, Q(2018).Food-drug interactions precipitated by fruit juices other than grapefruit juice: an update review.J Food Drug Anal,26(2),S61-S71.
6. Choi, YH,Chin, Y-W,Kim, YG(2011).Herb-drug interactions: focus on metabolic enzymes and transporters.Arch Pharm Res,34(11),1843-1863.
7. Chu, X-Y,Bleasby, K,Yabut, J(2007).Transport of the dipeptidyl Peptidase-4 inhibitor sitagliptin by human organic anion transporter 3,Organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.J Pharmacol Exp Therapeut,321(2),673-683.
8. Faria, AF,Marques, MC,Mercadante, AZ(2011).Identification of bioactive compounds from jambolão (Syzygium cumini) and antioxidant capacity evaluation in different pH conditions.Food Chem,126(4),1571-1578.
9. Guo, Heming,Fang, Chen,huang, Yun,Pel, Yufang,Chen, Linqui,hu, Ji(2016).The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: a systematic review and meta-analysis.Diabetes Res Clin Pract,121,184-191.
10. Gupta, RC,Chang, D,Nammi, S,Bensoussan, A,Bilinski, K,Roufogalis, BD(2017).Interactions between antidiabetic drugs and herbs: an overview of mechanisms of action and clinical implications.Diabetol Metab Syndrome,9(1),59.
11. Hennessy, M,Kelleher, D,Spiers, JP(2002).St Johns wort increases expression of P-glycoprotein: implications for drug interactions.Br J Clin Pharmacol,53(1),75-82.
12. Khathi, A,Serumula, MR,Myburg, RB,Van Heerden, FR,Musabayane, CT(2013).Effects of syzygium aromaticum-derived triterpenes on postprandial blood glucose in streptozotocin-induced diabetic rats following carbohydrate challenge.PLoS One,8(11),e81632.
13. Kishalay, J,Tushar, KB,Debidas, G(2015).Antidiabetic effect of Eugenia jambolana in streptozotocin induced diabetic male albino rats.Biomarkers Genom Med,3(7),116-124.
14. Li, Y,Xu, J,Yuan, C(2017).Chemical composition and anti-hyperglycaemic effects of triterpenoid enriched Eugenia jambolana Lam. berry extract.J Funct Foods,28,1-10.
15. Mohamed, J,Nazratun Nafizah, AH,Zariyantey, AH,Budin, SB(2016).Mechanisms of Diabetes-Induced Liver Damage: the role of oxidative stress and inflammation.Sultan Qaboos Univ Med J.,16(2),e132-e141.
16. Nair, AB,Jacob, S(2016).A simple practice guide for dose conversion between animals and human.J Basic Clin Pharm,7(2),27-31.
17. Pal, D,Mitra, AK(2006).MDR- and CYP3A4-mediated drugeherbal interactions.Life Sci.,78(18),2131-2145.
18. Pantalone, KM,Hobbs, TM,Wells, BJ(2015).Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system.BMJ Open Diabetes Res Care,3(1),e000093.
19. Sankhari, Jayanta M,Jadeja, RN,Thounaojam, MC,Devkar, Ranjitsinh(2010).Safety evaluation of Eugenia jambolana seed extract.Asian Pacific J Trop Med,3(12),982-987.
20. Sharma, SB,Nasir, A,Prabhu, KM,Murthy, PS,Dev, G.(2003).Hypoglycaemic and hypolipidemic effect of ethanolic extract of seeds of Eugenia jambolana in alloxan-induced diabetic rabbits.J Ethnopharmacol,85(2-3),201-206.
21. Shin, JW,Seol, IC,Son, CG(2010).Interpretation of animal dose and Human Equivalent dose for drug development.J Kor Orient Med.,31(3),1-7.
22. Sultana, B,Anwar, F,Przybylski, R(2007).Antioxidant activity of phenolic components present in barks of Azadirachta indica, Terminalia arjuna, Acacia nilotica, and Eugenia jambolana Lam. trees.Food Chem,104(3),1106-1114.
23. Sunil, M,Pratibha, C,Meerambika, M,Dhananjay, Y,Mousumi, D,Prasad, GBKS(2018).Antidiabetic potential of Eugenia jambolana ethanolic seed extract: effect on antihyperlipidemic and antioxidant in experimental streptozotocin-induced diabetic rats: a review.Adv Complement Alt Med,2(3),1-9.
24. Sushant, S,Kalyani, K,Patil, D,Sanjay, M,Kishori, A,Bhushan, P(2018).Herb-drug interaction of Nisha Amalaki and Curcuminoids with metformin in normal and diabetic condition: a disease system approach.Biomed Pharmacother,101,591-598.
25. Vincent, SH,Reed, JR,Bergman, AJ(2007).Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]Sitagliptin in humans.Drug Metab Dispos.,35(4),533-538.
26. Zhou, S,Lim, LY,Chowbay, B(2004).Herbal modulation of P-Glycoprotein.Drug Metab Rev,36(1),57-104.